All Posts
M-A | Effects of physical exercise on physical function in older adults in residential care
7 Jun, 2023 | 13:39h | UTCInvited commentary: Is there enough evidence to prescribe exercise to older adults living in residential care? – The Lancet Health Longevity
RCT | Immediate vs. delayed sequential bilateral cataract surgery: non-inferior in safety, higher cost-effectiveness
6 Jun, 2023 | 14:41h | UTCSafety, effectiveness, and cost-effectiveness of immediate versus delayed sequential bilateral cataract surgery in the Netherlands (BICAT-NL study): a multicentre, non-inferiority, randomised controlled trial – The Lancet (link to abstract – $ for full-text)
News Release: Cataract surgery: two-sided treatment better than one-by-one approach – Maastricht University
RCT | Tirzepatide outperforms insulin glargine in HbA1c reduction and weight loss in type 2 diabetes
6 Jun, 2023 | 14:39h | UTC
Commentary on Twitter
The SURPASS-AP-Combo trial shows that addition of #tirzepatide as 2L or 3L therapy is non-inferior & superior to insulin glargine for glycemic outcomes at 40 weeks in an Asia-Pacific (mostly Chinese) population w/ type 2 #diabetes. https://t.co/RDh2WSJ1wZ pic.twitter.com/nm6pPpVdxH
— Nature Medicine (@NatureMedicine) June 2, 2023
Review | How to understand the 95% confidence interval around the relative risk, odds ratio, and hazard ratio
6 Jun, 2023 | 14:37h | UTC
RCT | Perioperative pembrolizumab improves pathological outcomes, event-free survival in early-stage NSCLC
6 Jun, 2023 | 14:36h | UTCPerioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Presented at #ASCO23: In the KEYNOTE-671 trial, pts with resectable lung cancer were assigned to neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo. Two-year event-free survival was 62.4% with pembrolizumab & 40.6% with placebo.
— NEJM (@NEJM) June 3, 2023
RCT | Tirofiban results in greater likelihood of excellent outcome vs. aspirin in stroke without large vessel occlusion
6 Jun, 2023 | 14:33h | UTCTirofiban for Stroke without Large or Medium-Sized Vessel Occlusion – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Tirofiban for Stroke Without Large or Medium Vessel Occlusion – American College of Cardiology
Commentary on Twitter
Original Article: Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion (RESCUE BT2) https://t.co/Ul2kfAt9yX
Editorial: Expanding Treatment for Acute Ischemic Stroke beyond Revascularization: https://t.co/G8SAWnGJhS pic.twitter.com/21n0x4YqvK
— NEJM (@NEJM) June 1, 2023
SSAI Guideline | New-onset atrial fibrillation in critically ill adult patients
6 Jun, 2023 | 14:31h | UTC
Position Paper | Continuous electroencephalography in the intensive care unit
6 Jun, 2023 | 14:29h | UTC
Adrenaline auto-injector prescription for patients at risk of anaphylaxis: BSACI guidance for primary care
6 Jun, 2023 | 14:28h | UTC
Podcast | Insulin, type 2 diabetes, and hypoglycemia
6 Jun, 2023 | 14:25h | UTC#397: Insulin, Type 2 Diabetes, Fanny Packs, and Hypoglycemia with Dr. Jeff Colburn – The Curbsiders
Podcast | Hypopigmented and depigmented skin lesions in pediatrics
6 Jun, 2023 | 14:24h | UTC#84: Hypopigmented & Depigmented Skin Lesions: An En-LIGHT-ening Review – The Cribsiders
Podcast | Ascend your understanding of pelvic inflammatory disease
6 Jun, 2023 | 14:23h | UTC#83: Ascend Your Understanding of Pelvic Inflammatory Disease (PID) – The Cribsiders
Brief Review | What BP target is appropriate for pregnant patients with mild chronic hypertension?
6 Jun, 2023 | 14:20h | UTC
Review | Integrating eye care in low-income and middle-income settings
6 Jun, 2023 | 14:21h | UTCIntegrating eye care in low-income and middle-income settings: a scoping review – BMJ Open
Adrenal failure: an evidence-based diagnostic approach
6 Jun, 2023 | 14:16h | UTCAdrenal Failure: An Evidence-Based Diagnostic Approach – Diagnostics
M-A | Accuracy of diagnostic tests in cardiac injury after blunt chest trauma
6 Jun, 2023 | 14:15h | UTC
RCT | Befotertinib tops Icotinib in NSCLC progression-free survival, but increases serious adverse events
6 Jun, 2023 | 14:13h | UTCBefotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
M-A | Robot-assisted radical cystectomy versus open radical cystectomy
6 Jun, 2023 | 14:11h | UTC
Commentary from the author on Twitter (thread – click for more)
Our meta-analysis of 8 RCTS comparing open (ORC) and robot-assisted radical cystectomy (RARC) is now online on @EUplatinum 1/6https://t.co/b9TYe2yd9Y@JimCatto @Jkurol @drtanws @DrTanWP @SWilliams_MD @SBoorjian @roboturoloog @dipenjparekh @nikhilvasdevuro @ProfShamimKhan1 pic.twitter.com/M4u0iXTuwN
— Pramit Khetrapal (@p_khetrapal) May 10, 2023
Review | Patient-centered care in the management of cancer during pregnancy
6 Jun, 2023 | 14:10h | UTCPatient-Centered Care in the Management of Cancer During Pregnancy – ASCO Educational Book
See other articles in the series: 2023 ASCO Educational Book
Systematic Review | Impact of physical therapies on pain, function, and life quality in myofascial pain syndrome
6 Jun, 2023 | 14:07h | UTC
M-A | Significant non-alcoholic fatty liver disease prevalence in South Asia, many non-obese affected
6 Jun, 2023 | 14:00h | UTC
Global burden, risk factors analysis, and prediction study of ischemic stroke, 1990–2030
5 Jun, 2023 | 13:53h | UTCGlobal Burden, Risk Factors Analysis, and Prediction Study of Ischemic Stroke, 1990–2030 – Neurology
News Release: Worldwide Stroke Deaths Expected to Increase to Nearly 5 Million by 2030 – American Academy of Neurology
Commentary on Twitter
Published online: Global Burden, Risk Factors Analysis, and Prediction Study of Ischemic #Stroke, 1990–2030 https://t.co/nIH5mBQDtE#NeuroTwitter pic.twitter.com/WUfFQM5t7Z
— Neurology Journal (@GreenJournal) May 23, 2023
RCT | Noninferiority shown between DOACs and LMWH for recurrent VTE prevention in cancer patients
5 Jun, 2023 | 13:50h | UTCSummary: This unblinded, pragmatic, noninferiority randomized clinical trial aimed to assess the efficacy of direct oral anticoagulants (DOACs) against low-molecular-weight heparin (LMWH) in preventing recurrent venous thromboembolism (VTE) in patients with cancer. The study included 671 patients from 67 oncology centers, with a new clinical or radiological diagnosis of VTE.
Participants were randomly assigned to receive either a DOAC or LMWH for 6 months, and treating physicians selected and prescribed the drugs based on considerations like availability and drug-drug interactions. The primary outcome was the rate of recurrent VTE at 6 months. Findings revealed that the DOAC group had a recurrent VTE rate of 6.1% as compared to 8.8% in the LMWH group, showing noninferiority. Both groups had statistically similar rates of major bleeding and severe adverse events.
This pragmatic study included patients with advanced cancer and brain metastases, impaired performance status, and reduced liver or kidney function, making it more representative of routine oncology practice. Moreover, patient adherence to DOAC treatment was significantly higher than to LMWH. Nevertheless, the study had limitations, including the lack of blinding and underrepresentation of certain racial and ethnic groups.
In conclusion, this trial suggests that DOACs were noninferior to LMWH for preventing recurrent VTE in patients with cancer over a 6-month follow-up period, supporting the use of DOACs in this population for VTE prevention. Further research is needed to confirm these results and investigate long-term outcomes.
Article: Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial – JAMA (free for a limited period)
See also: Visual abstract
Commentary on Twitter
Among adults with cancer and VTE, direct oral anticoagulants were noninferior to low-molecular-weight heparin for preventing recurrent VTE over 6-month follow-up. #ASCO23 https://t.co/DP5RvlSYxe pic.twitter.com/rBJ99plopK
— JAMA (@JAMA_current) June 2, 2023
Review | Prevention of venous thromboembolism in patients with cancer
5 Jun, 2023 | 13:48h | UTCPrevention of venous thromboembolism in patients with cancer – The BMJ
RCT | Osimertinib improves overall survival in resected EGFR-mutated NSCLC, but validity of control group questioned on social media
5 Jun, 2023 | 13:46h | UTCOverall Survival with Osimertinib in Resected EGFR-Mutated NSCLC – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter by Dr. Vinay Prasad (recommended – click to see the video)
Here is the REAL @Plenary_Session on #ADAURA #ASCO23 #ASCO2023
38.5% of people who had recurrence got OSI (very low!)
That just isn't good enough
Brain staging is suboptimal= occult met disease
Would you let your mother be on the control arm and not get OSI on progression? pic.twitter.com/CU3jtrvFOj— Vinay Prasad MD MPH (@VPrasadMDMPH) June 5, 2023